Skip to main content
. 2022 Nov 11;7(5):856–865. doi: 10.1182/bloodadvances.2022008667

Table 2.

Cumulative incidences (95% CI) of csCMVi and secondary outcomes (CMV disease, OS, PFS, CIR, NRM) based on the risk of CMV infection and period

Low-risk (n = 156)
High-risk (n = 160)
Period 1n = 93 Period 2n = 63 P Period 1n = 93 Period 2n = 67 P
Letermovir (until wk 14) 0 (0%) 18/63 (28.6%) 0 (0%) 67 (100%)
csCMVi .003 < .001
 14-wk csCMVi 29.0% (20.2-38.5) 7.9% (2.9-16.3) 51.6% (41.0-61.3) 10.5% (4.6-19.2)
 24-wk csCMVi 33.3% (23.9-43.0) 11.2% (4.9-20.5) 52.7% (42.0-62.3) 16.9% (8.9-27.0)
 1-y csCMVi 34.4% (24.9-44.1) 12.9% (6.0-22.6) 53.8% (43.0-63.3) 28.2% (17.3-40.2)
CMV disease .85 .69
 14-wk CMV disease 0% 0% 3.2% (0.9-8.4) 0%
 24-wk CMV disease 1.1% (0.1-5.3) 1.7% (0.1-8.0) 4.3% (1.4-9.9) 1.5% (0.1-7.2)
 1-y CMV disease 2.2% (0.4-6.9) 1.7% (0.1-8.0) 4.3% (1.4-9.9) 3.3% (0.6-10.3)
OS .56 .08
 14-wk OS 92.5% (84.9-96.3) 90.5% (80.0-95.6) 87.1% (78.4-92.5) 89.6% (79.3-94.9)
 24-wk OS 88.2% (79.7-93.3) 85.6% (74.1-92.2) 80.6% (71.1-87.3) 89.6% (79.3-94.9)
 1-y OS 78.5% (68.7-85.6) 74.9% (61.8-84.1) 70.9% (60.5-79.0) 83.4% (71.0-90.8)
PFS .52 .06
 14-wk PFS 89.2% (80.9-94.1) 84.1% (72.5-91.1) 82.8% (73.5-89.1) 88.1% (77.5-93.8)
 24-wk PFS 80.6% (71.1-87.3) 76.1% (63.6-84.9) 76.3% (66.3-83.7) 86.6% (75.8-92.8)
 1-y PFS 69.9% (59.5-78.1) 65.3% (51.8-75.9) 62.3% (51.6-71.2) 77.6% (65.0-86.2)
CIR .60 .14
 14-wk CIR 4.3% (1.4-9.9) 6.4% (2.0-14.3) 4.3% (1.4-9.9) 1.5% (0.1-7.1)
 24-wk CIR 11.8% (6.3-19.3) 14.4% (7.0-24.2) 7.5% (3.3-14.1) 3.0% (0.6-9.3)
 1-y CIR 18.3% (11.2-26.8) 21.6% (12.1-32.8) 17.3% (10.4-25.7) 7.9% (2.9-16.2)
NRM .80 .31
 14-wk NRM 6.5% (2.6-12.7) 9.5% (3.8-18.3) 12.9% (7.0-20.6) 10.5% (4.6-19.2)
 24-wk NRM 7.5% (3.3-14.1) 9.5% (3.8-18.3) 16.1% (9.5-24.3) 10.5% (4.6-19.2)
 1-y NRM 11.8% (6.3-19.3) 13.1% (6.1-23.0) 20.4% (12.9-29.2) 14.5% (7.0-24.6)
Late csCMVi >14 wk .52 .20
 24-wk late csCMVi 6.5% (2.6-12.7) 3.4% (0.6-10.4) 9.7% (4.7-16.8) 7.9% (2.9-16.3)
 1-y late csCMVi 9.7% (4.7-16.7) 6.8% (2.1-15.1) 11.8% (6.2-19.3) 21.1% (11.5-32.7)